Hetero Drugs Project

8/10/2019 Hetero Drugs Project

1/69

PROJECT REPORT

ON

WORKING CAPITAL MANAGEMENT

OF

HETERO DRUGS LTD,ERRAGADDA, HYDERABAD.

Submitted in partial fulfillment of the requirement for the award of the degree of

MASTER OF BUSINESS ADMINISTRATION

To the

SCHOOL OF MANAGEMENT STUDIES

JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY KUKATPALLY,

HYDERABAD.

By

M.RAKESH

H.T.NO!"#UK"E##"$

At

VAAGDEVI ENGINEERING COLLEGE

BOLLIKUNTA, WARANGAL!%##%.

'Affiliated to Jawaharlal Nehru Technological University Kukatpally, Hyderabad(

')#"# !)#")(



2/69

BOLLIKUNTA! WARANGAL!%#& ##%

'Affiliated to Jawaharlal Nehru Technological University, Kukatpally, Hyderabad(

D*. M. JAGANMOHAN REDDY

M.Com. M. Phil., PhD

CO!ORDINATOR

CERTIFICATE

This is to certify that M*. M. RAKESH, H.T.No "#UK"E##"$ is a bonafide student of

MBA in this college during the academic year 20102012. !e has done the "ro#ect $or% entitled

+WORKING CAPITAL MANAGEMENT OF HETERO DRUGS LTD,ERRAGADDA,

HYDERABAD and com"leted the $or% in "artial fulfillment of the re&uirement for the a$ard

of MASTER OF BUSINESS ADMINISTRATION 'M.B.A(course, as "er the norms sti"ulated

by the JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY, K-/t0/11y,

Hy2e*/3/2.

The $or% is original and has not been submitted for any other degree or di"loma in "art

or in full.

CO!ORDINATOR


BOLLIKUNTA, WARANGAL 4 %##%


3/69

'Affiliated to Jawaharlal Nehru Technological University, Kukatpally, Hyderabad(

CERTIFICATE

This is to certify that the "ro#ect entitled +WORKING CAPITAL MANAGEMENT

OF HETERO DRUGS LTD, ERRAGADDA, HYDERABADhas been "re"ared by M*. M.

RAKESH, H.T.No "#UK"E##"$ under my su"er)ision. !e has com"leted this "ro#ect $or% as

"er the rules "rescribed by the JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY,

Hy2e*/3/2 for the "artial fulfillment of MASTER OF BUSINESS ADMINISTRATION. *t is

a bonafide $or% done by him and has not been submitted either in "art or full for any other

Degree or Di"loma of any other +ni)ersity.

'S*5 G. BHANU CHANDER(

PROJECT GUIDE

DECLARATION


4/69

* hereby declare that the Pro#ect entitled +WORKING CAPITAL MANAGEMENT OF

HETERO DRUGS LTD, ERRAGADDA, HYDERABAD is a bonafide $or% done by me as a

"art of re&uirement of MASTER OF BUSINESS ADMINISTATION 'M.B.A( at VAAGDEVI

ENGINEERING COLLEGEaffiliated to the JAWAHARLAL NEHRU TECHNOLOGICAL

UNIVERSITY, Hy2e*/3/2 during the year 20102012.

* also declare that this is the original $or% done by me and no "art of $or% has been

submitted either in "art or full for any Degree or Di"loma of any other uni)ersity or institution.

'M. RAKESH(

H.T.NO."#UK"E##"$

ACKNOWLEDGEMENTS


5/69

* ta%e this o""ortunity to e"ress my than%s to HETERO DRUGS LTD,

ERRAGADDA, HYDERABAD, $ho ga)e me this o""ortunity to carry out my "ro#ect in their

organi-ation.

* am )ery than%ful to Manager, S*5 K.MADHU KUMAR forhis )aluableguidance

and their constructi)e criticism, $hich $ere )ery hel"ful for the com"letion of the "ro#ect $or% in

this organi-ation.

* sincerely than% D*. M. JAGANMOHAN REDDY, coordinator, VAAGDEVI

ENGINEERING COLLEGE, Bo115-6t/, W/*/67/1, for gi)ing su""ort and encouragement

during my "ro#ect $or% in an efficient manner.

* sincerely than% to the efforts of S*5 G. BHANUCHANDER, 8/9-1ty :e:3e* o8

V//72e;5 E6756ee*567 Co11e7e, Bo115-6t/, W/*/67/1, for guiding and su""orting me in

com"letion of this "ro#ect.

This "ro#ect re"ort is dedicated to my "arents $ho are the source of su""ort and

encouragement, in e)ery as"ect of my life, education and career.

M.RAKESH

H.T.NO."#UK"E##"$

CONTENTS


6/69

S.NO CHAPTER P/7e No

* *T/D+CT* 010

** /3A/C! MT!D456 0718

*** CMPA6 P/9*4 1:81

*; DATA AA463*3 AD *T/P/TAT* 82


7/69

CHAPTER ! I

INTRODUCTION

INTODUCTION

)ery business needs funds for t$o "ur"oses, for its establishment and to

carry outs its daytoday o"erations. 4ong term funds are re&uired to create

"roduction facilities though "urchase of fied assets such as "lants and machinery,

land, building, furniture, etc. in)estments in these assets re"resent that "art of firm=s

ca"ital $hich is bloc%ed in a "ermanent or fied basis funds are also needed for short


8/69

term "ur"oses for that "urchase of ra$ marital, "ayment of $ages and other dayto

day e"enses, etc. these funds are %no$n as $or%ing ca"ital. *n sim"le $ords,

$or%ing ca"ital refers to that "art of the firm=s ca"ital $hich is re&uired for financing

short term or current assets such as cash, mar%etable securities, debtor and

in)entories.

*n the $ords of 3!+B*, >$or%ing ca"ital is the amount of funds necessary

to co)er the cost or o"erating the enter"rise?.

According to 53TB/5, >circulating ca"ital means current assets of a

com"any that are changed in the ordinary course of business from one form to

another form, as "er eam"le from cash to in)entories, in)entories to recei)ables,

recei)ables into cash?.

*n sim"le $ords, $or%ing ca"ital refers to that "art of the firm=s ca"ital $hich

is re&uired for financing short term or current assets such as cash, mar%etable

securities, debtors and in)entories. 9unds, thus, in)ested in current asst %ee"

re)ol)ing fast and are being constantly con)erted into cash and this cash flo$s out

again in echange for other current assets. !ence, it is also %no$n as *e;o1;567 o*

95*9-1/t567 9/05t/1or short term ca"ital.

That $or%ing ca"ital refer to that difference bet$een current assets and

current liabilities, it is ecess of current assets o)er current liabilities.

@or%ing ca"ital current assetscurrent liabilities

O0e*/t567 Cy91e o8 Wo*567 C/05t/1

*t is clear that $or%ing ca"ital is re&uired because of the time ga" bet$een the

sales and their actual reali-ation into cash. This time ga" is technically called as

>"erating cycle? of the business.

*n case of a manufacturing com"any the o"erating cycle is the length of time

necessary to com"lete the follo$ing cycle of e)ents.

Con)ersion of cash into ra$ materials.


9/69

Con)ersion of ra$ material into $or% in "rogress.

Con)ersion of $or% in "rogress into finished goods.

Con)ersion of finished goods into accounts recei)able, and

Con)ersion of account recei)able into cash.

This cycle $ill be re"eated again and again. The s"eed $ith $hich the

$or%ing ca"ital com"letes one cycle determines the re&uirements of $or%ing ca"ital

4onger the "eriod of the cycle larger is the re&uirement of $or%ing ca"ital.

The o"eration cycle of manufacturing business can be sho$n as the follo$ing chart.

Nee2 o8


10/69

Technically this is refers to o"erating or cash cycle. *f the com"any has certain amount of

cash, it $ill re&uire for "urchasing the ra$ material may be a)ailable on credit basis.

M/6/7e:e6t o8 . De3to*= :/6/7e:e6tdebtors management identify the a""ro"riate credit "olicy i.e.

credit terms $hich attract customers, such that any im"act on cash flo$s and the cash

con)ersion cycle $ill be offset by increased re)enue and hence /eturn on ca"ital.

?. Sho*t Te*: F56/69567 short term financing identify the a""ro"riate source of

financing, gi)en the cash con)ersion cycle.

CLASSIFICATION

Wo*567 9/05t/1 :/y 3e 91/==585e2 56 to t


11/69

There are t$o conce"ts of $or%ing ca"ital management

1. 5ross $or%ing ca"ital

5ross $or%ing ca"ital refers to the firm=s in)estment in current assets. Current

assts are the assets $hich can be con)ert into cash $ithin year includes cash, short term

securities, debtors, bills recei)able and in)entory.

2. et $or%ing ca"ital

et $or%ing ca"ital to the difference bet$een current assets and current

liabilities. Current liabilities are those claims of outsiders $hich are e"ected to mature

for "ayment $ithin an accounting year and include creditors, bills "ayable and

outstanding e"enses. et $or%ing ca"ital can be "ositi)e or negati)e efficient $or%ing

ca"ital management re&uired that firms should o"erate $ith some amount of net $or%ing

ca"ital, the eact amount )arying from firm to firm and de"ending, among other thins on

the nature of industries, net $or%ing ca"ital is necessary because the cash out flo$s and

inflo$s do not coincide. The cash out flo$s resulting from "ayment of current liabilities

are relati)ely "redictable. The cash inflo$ are ho$e)er difficult to "redict. The more

"redictable the cash inflo$s are the less net $or%ing ca"ital $ill be re&uired.

The conce"t of $or%ing ca"ital $as, first e)ol)ed by arl Mar. Mar used

the term )ariable ca"ital= means outlays for "ayrolls ad)ance to $or%ers before the

com"letion or $or%. !e com"ared this $ith constant ca"ital= $hich according to him in

nothing but dead labor=. This )ariable ca"ital= is nothing $age fund $hich remains

bloc%ed in terms of financial management, in $or%ing "rocess along $ith the other

o"erating e"enses until it is released through sale of finished goods although Mar did

not mentioned that $or%ers also ga)e credit to the firm by acce"ting "eriodical "ayment

of $ages $hich funded a "ortioned of @.*.P. the conce"t of $or%ing ca"ital, as $eunderstand today $as embedded in his )ariable ca"ital=.

ON THE BASIS OF TIME


12/69

n the basis of conce"t $or%ing ca"ital can be classified as gross $or%ing

ca"ital and net $or%ing ca"ital. n the basis of time, $or%ing ca"ital may be classified

asE

". Pe*:/6e6t


13/69

:. Pay go)ernment taation and "ro)iders of ca"ital di)idends


14/69

reasonable relati)e to sales, ho$ ra"idly are recei)ables being collected, and the

slo$ "aying customers.

8. *n)entory can be as much as


15/69

The o"erating efficiency of the firm relates to the o"timum utili-ation of

resources at minimum costs. The firm $ill be effecti)ely contributing in %ee"ing the

$or%ing ca"ital in)estment at a lo$er le)el if it is efficient to controlling o"eratingcosts and utili-ing current assets. The use of $or%ing ca"ital is im"ro)ed and "ace of

a cash con)ersion cycle is accelerated $ith o"erating efficiency.

&. BUSINESS FLUCTUATIONS

Most firm e"erience seasonal and cyclical fluctuation in the demand for their"roducts and ser)ices. This business )ariation effects the $or%ing ca"ital

re&uirements es"ecially the tem"orary $or%ing ca"ital re&uirement of the firm. @hen

there is an u"$ard s$ing in the economy, sales $ill increase and )ice)ersa.

$. PRODUCTION POLICY

A steady "roduction "olicy $ill cause in)entories to accumulate during theoffseason "eriods and the firm $ill be e"osed to greater in)entory cost and ris%.

Thus, if the cost and ris%s of maintaining a constant "roduction schedules are high,

the firm may ado"t the "olicy of )arying its "roduction schedules in accordance $ithchange in demand.

. GROWTH AND EPANSION ACTIVITIES

The $or%ing ca"ital needs of firm increases it gro$th in terms of sales of

fied assets. *t it is difficult to "recisely determine the relationshi" bet$een )olume of

sales and the $or%ing ca"ital needs. The critical fact ho$e)er that is the need forincreased $or%ing ca"ital funds does not follo$ gro$th in business acti)ities but

"recedes it.


16/69

CHAPTER ! II

RESEARCH METHODOLOGY

RESEARCH METHODOLOGY

5ood research is carefully "lanned and is conducted "rofessionally and generates

de"endable data. Data generated from good research can be used reliably for managerial

decision ma%ing.

1. The research should be described in details. ach ste" in the research "rocess

should be e"lained in details so that another researcher $ill be able to re"eat the

research. The sources of the data should be re)ealed and the means by $hich they

$ere obtained should be made clear.


17/69

2. /esearcher should ta%e care to "rotect the "ri)acy of the res"ondents. The

researcher should be ta%ing into consideration the $elfare of the "artici"ants of

the studies as $ell as that of their client.

8. Data obtained from research should be used to #ustify the conclusion. Personal

inter"retations or e"eriences of the researcher should be a)oided.

:. Any dra$bac% in the design should be re)ealed by the researcher and its effects

on the finding should be estimated.

BENEFITS OF RESEARCH

1. /esearch can hel" businesses to communicate $ith their sta%e holders li%e

customers, su""liers etc. they can de)ice im"ortant conclusions through business

research.

2. /esearch hel"s businesses to identify the o""ortunities and threats.

8. /is%s and uncertainties can be minimi-ed through business research. /esearch is

)ery im"ortant for e)aluating the "rogress of the business and to e"loit more

o""ortunities

:. *t can hel" the business to trac% their benchmar% and to a)oid any loss $hich they

can incur $ithout ha)ing mar%et and business information.

OBJECTIVES OF THE STUDY

The follo$ing are the ob#ecti)e of the study.

1. To study the $or%ing ca"ital management of !T/ D/+53 4*M*TD.

2. To eamine the feasibility of "resent system of managing cash, debtor andin)entory.

8. To study the management of current assets and current liabilities of !T/

D/+53 4*M*TD.

:. To e)aluate the financial "osition of the com"any.


18/69


19/69

:. The study has concentrated only on the $or%ing ca"ital of the com"any. The other

financial as"ects or com"onents $ere ignored.


20/69

". P*5:/*y D/t/

*n "rimary data collection, the data $ill be collected by using &uestionnaires and

inter)ie$s.

There are many methods of collecting "rimary data and the main methods includeE

1. *nter)ie$s

2. bser)ation

). Se9o62/*y D/t/

3econdary data a)ailable from "ublishers, inhouse database, research

agencies etc. it constitutes readymade information that can be used for research

"ur"ose $ith minimal analysis. !o$e)er, the research should bear in mind

secondary data is "ublished for "ur"ose other than the current research.

3econdary data hel"s researchers to sa)e time. @hile "rimary research

ta%es a considerable amount of time in the form of collecting and analy-ing the

data, secondary data offers readymade solutions.

SOURCES OF DATA

Methodology is systematic "rocess of collecting information in order to analy-e

and )erify a "henomenon, the collection of the data t$o "rinci"les "rocess.

1. Primary data

2. 3econdary data

". P*5:/*y 2/t/

The data that is collected first time for any statistical in)estigation and is used

in the statistical analysis is termed as "rimary data.


21/69

The "rimary data is obtained by ha)ing "ersonal inter)ie$s $ith the officials of

the com"any, interacting $ith the manager I other concerned eecuti)es at the

administrati)e office of the com"any.

). Se9o62/*y 2/t/

the data $hether "ublished, $hich ha)e been already collected and "rocessed

by some agency or "erson and ta%e o)er from them and used by any other agency

or "erson for their statistical $or% are termed as secondary data.

The secondary data $as collected mainly from the follo$ing source.

1. Annual re"ort

2. Manuals and maga-ines.

8. /eference to #ournals, tet boo%s and ne$s "a"ers.

:. Com"any $ebsite .com.


22/69

CHAPTER ! III

COMPANY PROFILE

COMPANY PROFILE

". H5=to*y o8 HETERO

). Fo-62e* o8 HETERO

>. M/60o


23/69

&. V5=5o6 ;/1-e= o8 HETERO

$. B-=56e== 8o9-= o8 HETERO

. D*-7 25=9o;e*y

. A115/69e= 0/*t6e*=h50=

"#. Re=e/*9h 2e;e1o0:e6t

"". HETERO DRUGS 9-1t-*e

"). Wo*01/9e eth59=

">. So95/1 *e=0o6=53515t5e=

"?. Ne


24/69

He/2-/*te*= !yderabad, *ndia

Key 0eo01e Dr. B. Partha 3aradhi /eddy 'CMD(

E:01oyee= )er H,HH

We3=5te $$$.heterodrugs.com

!etero is a research based global "harmaceutical com"any focused on

de)elo"ment, manufacturing and mar%eting of Acti)e Pharmaceutical *ngredients 'AP*s(,

*ntermediate Chemicals I 9inished Dosages. )er since its establishment in 1778,

!etero sho$ed a tradition of ecellence and dee" sense of commitment in de)elo"ing

cost effecti)e "rocesses to offer $ide range of affordable drugs.

!etero is building on the strengths of )ertical integration in disco)ery research,

"rocess chemistry, AP* manufacturing, formulation de)elo"ment and commerciali-ation.

!etero is a leading international su""lier $ith a rich "ortfolio of o)er 200 "roducts from

$ide range of thera"eutic categories both in acti)e "harmaceutical ingredients and

finished dosages.

!etero=s manufacturing facilities are c5MP com"liant meeting global standards in

terms of infrastructure and systems. Ma#ority of them are a""ro)ed by the )arious

regulatory authorities of +39DA, @!5ene)a, Australian T5A, 3"anish agency of

medicines I health care "roducts, A;*3ABra-il, *DAetherlands etc.@ith full
http://en.wikipedia.org/wiki/Hyderabad,_Andhra_Pradeshhttp://en.wikipedia.org/wiki/Indiahttp://en.wikipedia.org/wiki/Employmenthttp://en.wikipedia.org/wiki/Websitehttp://www.heterodrugs.com/http://en.wikipedia.org/wiki/Hyderabad,_Andhra_Pradeshhttp://en.wikipedia.org/wiki/Indiahttp://en.wikipedia.org/wiki/Employmenthttp://en.wikipedia.org/wiki/Websitehttp://www.heterodrugs.com/


25/69

fledged mar%eting ca"abilities, the com"any has been able to mar%et its "roducts in o)er

18 countries across the globe.

HISTORY OF HETERO

stablished in the year 1778, $ith the motto

to be the best in the AP* manufacturing, !etero

today embodies the )ision of a to" notch "layer in

de)elo"ing and commerciali-ing "roducts catering

to a )ariety of thera"eutic categories, integrating

into a 4eading finished dosage manufacturer.

True to the 3tatement, J@here the 9uture 3tarted 6esterdayJ, $ith a

foresight on the current trends in the Pharmaceutical Mar%et, !etero has gro$n from

strength to strength, combining its /esearch 3trengths, Manufacturing Ca"abilities, and

!uman /esources and $ell established &uality management system.

@ith fullfledged mar%eting ca"abilities, the com"any has been able to mar%et its

"roducts in o)er 100 countries in Asia, Middleeast, astern uro"e and 4atin America.

@ith its com"liance to the most stringent regulatory re&uirements, !etero has today

gained foothold to mar%et se)eral of its AP*s in the +nited 3tates, Canada and uro"e.

@ith all si manufacturing facilities being su""orted by ecellent infrastructure

and com"liance to the 5MP re&uirements, !etero has crossed numerous milestones in a

com"arati)ely short "eriod since its ince"tion.

Fo-62e*

Whe*e the 8-t-*e =t/*te2 ye=te*2/y....

... Wo*= / 2/y /he/2 o8 8-t-*e....

A V5=5o6/*y S95e6t5=t

Dr. Bandi Parthasaradhi /eddy, Chairman I Managing Director of !etero grou"

is academically endo$ed $ith a Post 5raduate and Doctoral degrees $ith distinction in


26/69

the field of synthetic chemistry. Prior to founding of !etero Drugs 4imited, Dr. B.P.3

/eddy had a stint in leading "harmaceutical com"anies as the head of the /esearch I

De)elo"ment di)ision. !is shar" analysis and ability to synthesi-e )arious chemical

com"ounds lead to the disco)ery of ne$ "rocesses, cost effecti)e schemes for

manufacturing of )arious "harmaceutical "roducts. During the said "eriod Dr.B.P.3

/eddy has the credit of introducing many ne$ molecules for the first time in *ndian

"harmaceutical mar%et.

A )isionary the $orld %no$s as Dr. B.P.3./eddy, is the dri)ing force behind this

gro$ing "harmaceutical "henomenon called >!T/?. Dr.B.P.3./eddy=s dream child,

!etero $as born in the year 1778 as a small AP* unit. Today, 1H years later, the name is

synonymous $ith leadershi" in "harmaceuticals $ith more than 1 manufacturing units

and 000 em"loyees. An entity that is gro$n in stature by )irtue of its combined strength

in research, manufacturing and mar%eting.

Dr. B.P.3./eddy steered !etero to$ards the forefront of global "harmaceutical

industry $ith his )ision to be recogni-ed as an aggressi)e com"any that combines its

strength of /ID and manufacturing $ith definite ad)antages in terms of cost and

chemistry $ith a strong em"hasis on &uality of the "roducts.

Dr. B.P.3./eddy is no$ focusing on gi)ing ne$ dimensions to !etero in terms of

research and inno)ation "rograms in disco)ery research to ta%e the com"any to greater

heights.

MANPOWER IN HETERO GROUP

1. !etero Drugs 4imited 1H8H

2. !etero 4abs 4imited


27/69

MANAGEMENT

3.. AM D3*5AT*


28/69

1.

2.

8.

:.


29/69

Managing Director

5eneral Manager

De"uty 5eneral Manager

Assistant 5eneral Manger

Manager

Assistant Manager

3enior ecuti)e

ecuti)e

Kunior ecuti)e

Assistant ecuti)e

Trainee

V5=5o6 /62 ;/1-e=

!etero belie)es in >@!/ T! 9+T+/ 3TA/TD 63T/DA6

@/3 A DA6 A!AD 9 9+T+/.?

!T/=3 Ambition is to be an aggressi)e "layer in "harmaceutical mar%ets

combining **P/ s%ills, manufacturing ca"abilities, strong human resources in"uts and

mar%eting strengths.

;alues in "ursuit of ecellenceE

*nno)ation

Creati)ity

/eliability


30/69

Accessibility

Cost effecti)eness

Luality

Accuracy

Customer delight

co friendly

!etero )isuali-es itself as an aggressi)e "layer in the global "harmaceutical

scenario su""lying generics de)elo"ed combining intellectual "ro"erty research strength

and strong human resource in"uts

The com"any )alues the conce"ts of ha)ing social res"onsibilities in the

course of its assents to greater heights. *t strongly belie)es in focusing on customer

re&uirements and deli)ering the "roducts at the right "ace. !etero considers its human

resource as the core of all its ca"abilities and belie)es in ta""ing and honing the talent of

its members to reach the -enith of success. *t belie)es in continuous e)aluation and

im"ro)ement in all the factors that contribute in transforming the organi-ation into a

global to rec%on. !etero ta%es recogni-e the fact that the "rocesses that it de)elo"s all eco

friendly and it should not result in any conse&uence that harms the ecological harmony.

M5==5o6

!etero=s mission is to be a globally acclaimed "harmaceutical com"any,

meeting the re&uirement of healthcare imbibing the "hiloso"hy of both commercial and

social concerns, dri)en by research and manufacturing ca"abilities.

St*e67th

3trong em"hasis on research and de)elo"ment

Ability to de)elo" "rocesses for a large range of thera"eutic categories

Ability to orient and ada"t to the changing facets of industry "articularly in

terms of regulations, intellectual "ro"erty and manufacturing ca"abilities


31/69

Cohesi)e teams of s%illed "rofessionals in all $ings related to research,

manufacturing and mar%eting

3trong customer base and mar%et "resence

A strong commitment to$ards the society to "ro)ide timely su""ort by"ro)iding life sa)ing drugs at relati)ely lo$ costs, short s"an of time.

G1o3/1 0*e=e69e

!etero e"orts its "roducts across different regions N +3A, Canada, uro"e,

Ka"an, 4atin America, Africa, Middle ast, 9ar ast, Australia, /ussia I C*3, in the

$orld and is catering to the re&uirements of around 18 countries in the $orld.

B-=56e== 8o9-=

A9t5;e 0h/*:/9e-t59/1 567*e25e6t=

!etero is one of the largest manufacturer and su""lier of Acti)e

Pharmaceutical *ngredients 'AP*=s( catering to the e)er increasing re&uirements of the

global "harmaceutical mar%et.

The infrastructure a)ailable $ith !etero for manufacturing of Acti)e

Pharmaceutical *ngredients and the intermediate chemicals is one of the best, $ith 3tate

ofthe Art facilities designed to meet the global standards and c5MP.

@ith 11 AP* manufacturing facilities in o"eration, !etero has been able

to manufacture more than 200 AP*s, and su""ly to different mar%ets. G of the AP*

facilities are a""ro)ed by +39DA, T5A, +, PMDA, 9DA and @!.

!etero is a trusted su""lier of se)eral AP*s in $ide range of thera"eutic

categories and the largest su""lier of com"lete range in antiretro)iral "roducts. !etero

also has dedicated facility for manufacturing of ncology "roducts.

F565=he2 2o=/7e=


32/69

!etero has $orldclass facilities for manufacturing $ide range of finished

dosages. As a leading inno)ationdri)en cor"oration, !etero is de)elo"ing a gro$ing

"ortfolio of "harmaceutical "roducts to meet some of the $orldOs most urgent medical

needs. Today !etero is manufacturing "roduct "ortfolio of o)er 200 "roducts in ma#or

thera"eutic areas, $ith an em"hasis on antiretro)iral, gastrointestinal, cardio)ascular,

antide"ressants Fanti"sychotic, anti diabetics, "ain management, antiinfecti)e,

dermatology and oncology. !etero has

9our finished dosage manufacturing facilities, out of $hich t$o are +39DA,

a""ro)ed facilities.

Dedicated ncology facility

ffers

1. *n#ectables

2. 3olidF4i&uid oral dosages

8. intments

:. 3oft gelatin ca"sules


33/69

de)elo"ment. T$o "roducts are e"ected to be commerciali-ed in *ndia for oncology

and ne"hrology indications by 201112.

D*-7 25=9o;e*y

!etero started disco)ery research $ith the focus on de)elo"ing Cs in selected

thera"eutic areas. 3cientists at Drug Disco)ery Di)ision are $or%ing on the

follo$ing "ro#ects E

o AT*!*; /esearch

o AT*!C; /esearch

o Diabetes /esearch

ur business strategy is to out license early stage disco)ery molecules and to e"lore

early stage disco)ery collaborations to maimi-e the "otential of our disco)ery "ro#ects.

A115/69e= P/*t6e*=h50=

At !etero, $e )alue alliancesF"artnershi"s. !etero has de)elo"ed

"roducti)e alliances and "artnershi"s that ad)ance our ca"acity to de)elo" inno)ati)e

medicines at lo$er costs. ur collaborations ha)e "roduced strong, enduring "artnershi"s

and yielded consistent success in the mar%et "lace. A glance at our trac% record highlights

some of our achie)ements $hile illustrating the di)ersity among our "artners and the"roducts. !etero is regarded as one of the best com"anies in the $orld to $or% for, and

generations of !etero em"loyees ha)e sustained a culture that )alues ecellence,

integrity, and res"ect for "eo"le.

Re=e/*9h De;e1o0:e6t

/esearch I De)elo"ment is the foundation of !etero=s "hiloso"hy of de)elo"ing

costeffecti)e, high &uality and safe medicines to society. !etero /esearch 9oundation is

one of the most inno)ati)e, "roducti)e, and res"ected scientific research organi-ations

$hich are recogni-ed by the De"artment of 3cience I Technology, 5o)ernment of *ndia.

!etero /esearch 9oundation '!/9( has a team of o)er :00 dedicated scientists

$or%ing in the areas of Process, Analytical and Disco)ery /esearch. / I D centre


34/69

conforms to international standards and has ad)anced e&ui"ment for both basic and

a""lied research.

P*o9e== RD

!/9 has de)elo"ed "rocess for 1


35/69

C/*ee*= /t HETERO

!etero=s strength lies in the talent and commitment of the "eo"le $ho $or% for us.

!etero is on the "ath of "rogress and e"anding )ery fast in all its )erticals. ""ortunities

eist in for talented "eo"le of di)erse bac%grounds in )arious de"artments. !etero creates

an en)ironment for "ersonal and "rofessional gro$th of em"loyees.

A healthy $or%life balance is su""orted through %no$ledgedri)en $or%

en)ironment $here ideas and s%ills are )alued $here "eo"le can reali-e their full

"otential through dedicated training "rograms and $here indi)idual contribution is

res"ected, recogni-ed and re$arded.

The Hete*o 2*-7= 15:5te2 9-1t-*e

C-=to:e* Fo9-=e2 /62 Pe*8o*:/69e D*5;e6 $here both eternal and internal

customers are accorded the highest "riority and $here e)eryone is sensiti)e to

Commitments, time I cost and focuses on deli)ering inno)ati)e affordable

medicines globally.

E6t*e0*e6e-*5/1 /62 566o;/t5;e $here genuine mista%es are tolerated,

intelligent ris% N ta%ing is encouraged and "eo"le feel a sense of em"o$erment. E7/15t/*5/6 /62 T*-=t567 $here ran% and status consciousness is lo$, leadershi"

$al%s the tal%, $here credibility I trust$orthiness are cham"ioned and leaders

"ro)ide access to "eo"le, resources and information.

F1e531e /62 A2/0t5;e $here change is $elcome and initiati)es are im"lemented

$ith sincerity and commitment, di)ersity is understood and acce"ted and mutual

res"ect for di)ersity and )arious ethnic cultures coeist.

Wo* 01/9e eth59=

O0e6 2oo* 9o::-659/t5o6:

!etero Drugs maintains an o"endoor culture for communication to assist

$ith em"loyee concerns. *f em"loyee does not feel comfortable discussing concerns $ith

his Fher su"er)isor or manager, they contact the net le)el of management. !etero Drugs


36/69

belie)es that o"en communication is essential to a successful $or% en)ironment and all

em"loyees should feel free to raise concerns $ithout fear of re"risal.

Co-*te=y

They de)elo" an attitude or hel"fulness to$ards their customers,

su""liers, )endors, and their fello$ em"loyees. Courtesy is a ma#or com"onent of good

human relations. 5ood tele"hone eti&uette is also im"ortant $hen dealing $ith others,

both inside and outside of !etero Drugs.

D*e== 9o2e

m"loyees are bet ad)ised to be formally attired on all $ee%days so as to

reflect confidence and "rofessionalism. n $ee%ends '2ndand :th9ridays at head office

and all $or%ing 3aturdays at all 8 locations(, em"loyees could $ear informal $ear as

follo$s.

M/1e e:01oyee=

Business casual '$ee%days(E collared shirts, Trousers, leather shoes 'Blac%FBro$n(

Casual '9ridays(E 3hirtsF collared Tshirts, Trousers and s"orts shoes

Fe:/1e e:01oyee=

9ormal $earE 3arees, 3al $ar %ames, formal shirts, full s%irts, trousers and sandals

*nformal $earE collared Tshirts, full s%irts, shirts, trousers, and sandals.

ID C/*2=

All em"loyees are issued an id card $ithin one $ee% of #oining, and it is

ad)ised that the cards are al$ays $orn on "erson $hile on duty. *n case of the card being

lost or damaged, the "ersonnel de"artment needs to be informed immediately.

Le/;e=


37/69

m"loyees are re&uested to a)ail lea)e as "er eligibility unless eigencies

demand other$ise. Planned lea)e need be a""ro)ed by the incharge, in the "rescribed

form a)ailable $ith the "ersonnel de"artment.

So95/1 *e=0o6=53515ty

!etero recogni-es its obligations to$ards the society and as a socially res"onsible

organi-ation $e stri)e to ta%e care of the less "ri)ileged sections of our society. @e

etend our e"ertise to transform the li)es of our "eo"le and ma%e a difference to the

society. *n this initiati)e, !etero has ada"ted fe$ )illages for their o)erall de)elo"ment.

E2-9/t5o6

!etero assists in setting u" of schools $here there is no access to education

facilities, "ro)iding financial assistance to the "oor students $ho ha)e "romising

academic record, ada"ting schools.

S0o*t=

3"onsors athletics from )arious educational institutions to "artici"ate in ational

and *nternational le)el com"etition.

Me259/1

!etero conducts "eriodical medical cam"s at )arious locations in socially bac%$ard

areas to "ro)ide timely medical assistance to the needy. !etero has liberally donated

medicines to the 5o)ernment of *ndia, 5o)ernment of A.P. and to )arious !os"itals.

Ne


38/69

The total unit area is H< acres and $ith t$o manufacturing facilities. This facility

offers a huge "roduction ca"acity of 1 billion tablets and ca"sules "er annum. *t has a

dedicated ncology facility $ith a "roduction ca"acity of 200 million tablets I ca"sules,

1< million li&uid in#ectable )ials I 1< million lyo"hili-ed *n#ectables.

This @orldclass facility is meeting the c5MP and regulatory re&uirements, $ith

integrated &uality management system in "lace. All &uality control *nstruments are 21

C9/ com"liant. @al% in ty"e stability chambers $ith global re&uirements for stability

study and *ntegrated building management system from !oney $ell +3A , 4yo"hili-er

;*/T*3 +3A, 4i&uid 9illing machine from B3C! N 5ermany, ma%es this

manufacturing facility at "ar $ith the best in the $orld.

A0*51)#"#

Hete*o *e9e5;e= te6t/t5;e /00*o;/1 8o* Te6o8o;5* 25=o0*o51 8-:/*/te t/31et= 8*o:

USFDA

!etero is "leased to announce that it has recei)ed the tentati)ely a""ro)al for

Tenofo)ir diso"roil fumarate from the +3 9ood I Drug Administration '+39DA(.

A Tenofo)ir tablet 800 mg is generic e&ui)alent to ;iread tablets 800 mg of

5ilead 3ciences. Tenofo)ir belongs to a class of antiretro)iral drugs %no$n as nucleotide

analogue re)erse transcri"tase inhibitors 'n/T*s(, $hich bloc% re)erse transcri"tase, an

en-yme crucial to )iral "roduction in !*;infected "eo"le. Tenofo)ir is indicated in

combination $ith other antiretro)iral agents for the treatment of !*;1 infection in

adults.


39/69

No;)##

Hete*o *e9e5;e= te6t/t5;e /00*o;/1 o8 L/:5;-256e /62 Te6o8o;5* 85e2 2o=e 9o:356/t5o6

t/31et=, >##:7>##:7 t/31et= 8*o: USFDA

n o)ember


40/69

"

!ighest e"orter a$ard against stiff com"etition from internationally recogni-ed

domestic com"etitors.

"!"&

To" Chemeil a$ard for "orts.

ational a$ard for JBe=t E88o*t= 56 Re=e/*9h /62 De;e1o0:e6tJ from the De"artment

of 3cientific and *ndustrial /esearch, Ministry of 3cience and Technology, 5o)ernment

of *ndia, in the year 177G.


41/69

CHAPTER ! IV

DATA ANALYSIS

AND

INTERPRETATION


42/69

STATEMENT SHOWING CHANGES IN WORKING CAPITAL

FOR THE YEAR ENDED )##$!)##

'R=. I6 C*o*e=(

PARTICULARS

A= o6 >"=tDe9e:3e* Ch/67e= 56 Wo*567 9/05t/1

)##$'R=( )##'R=( I69*e/=e'R=( De9*e/=e'R=(

CURRENT ASSETS

*n)entories

3undry Debtors

Cash and Ban% Balance

4oans and ad)ances

80.:0

2.82

% >%.)$

NET WORKING CAPITAL 'A!B( #.) >#.$$ >.> .#

*ncrease F Decrease in et @or%ing

Ca"ital

?.%) ?.%)

TOTAL #.) #.) .# .#


43/69

INTERPRETATION

9rom the abo)e table, it can be obser)ed that

1. *n)entories $ere increased by /s.:.11 crores, due to increased "urchase of ra$ materials.

2. 3undry debtors $ere decreased by /s.21.1: crores, due to decrease in credit sales.

8. Cash and ban% balances $ere decreased by /s.


44/69

FOR THE YEAR ENDED )##!)##

'R=. I6 C*o*e=(

PARTICULARS

A= o6 >"=tDe9e:3e* Ch/67e= 56 Wo*567 9/05t/1

)##'R=( )##'R=( I69*e/=e'R=( De9*e/=e'R=(

CURRENT ASSETS

*n)entories

3undry Debtors


4oans and ad)ances

8:.% >>.&% "".#>

NET WORKING CAPITAL 'A!B( >#.$$ &).& ??.#" "".)


Ca"ital

>)." >)."

TOTAL &).& &).& ??.#" ??.#"

INTERPRETATION



45/69

1. *n)entories $ere increased by /s.20.80 crores, due to increased "urchase of chemicals.

2. 3undry debtors $ere increased by /s.1


46/69

PARTICULARS

A= o6 >"=tDe9e:3e* Ch/67e= 56 Wo*567 9/05t/1

)##'R=( )#"#'R=( I69*e/=e'R=( De9*e/=e'R=(

CURRENT ASSETS

*n)entories

3undry Debtors


4oans and ad)ances

>.&% >$.& ?.#& .#

NET WORKING CAPITAL 'A!B( &).& ">>.> $.& .#


Ca"ital

$#.$ $#.$

TOTAL ">>.> ">>.> $.& $.&

INTERPRETATION


1. *n)entories $ere increased by /s.1


47/69

:. 4oans and ad)ances $ere increased by /s.1H.7 crores, due to the com"any ha)e

"ro)ided more loans to the em"loyees and also ad)anced to the su""liers of ra$

materials.


48/69

PARTICULARS

)#"#'R=( )#""'R=( I69*e/=e'R=( De9*e/=e'R=(

CURRENT ASSETS

*n)entories

3undry Debtors


4oans and ad)ances

H0.2.&" ).%% ?.?

NET WORKING CAPITAL 'A!B( ">>.> "%".$$ )).?) ?.?


Ca"ital

"$.? "$.?

TOTAL "%".$$ "%".$$ )).?) )).?)

INTERPRETATION


1. *n)entories $ere increased by /s.:.2< crores, due to increased "urchases.

2. 3undry debtors $ere increased by /s.


49/69


50/69

CURRENT ASSETS

*n)entories

3undry Debtors


4oans and ad)ances

H:..&" ).) ").>? ".#"

NET WORKING CAPITAL 'A!B( "%".$$ "%).# ".? "."&


Ca"ital

#.>) #.>)

TOTAL "%).# "%).# ".? ".?

INTERPRETATION


1. *n)entories $ere decreased by /s.


51/69

G. Pro)isions $ere increased by /s.1.01 crores, due to decrease in sundry debtors.

H. The o)erall net $or%ing ca"ital has been increased by /s.0.82 crores, due to increase in

current assets.

. The net $or%ing ca"ital "osition of the com"any $as sho$ing a)erage "erformance.

CURRENT RATIO

Current ratio is the common ratio for measuring li&uidity, being related to $or%ing ca"ital

analysis it is also called as the current ratio, $hich e"resses the relationshi" bet$een

current assets and current liabilities. The current ratio is the ratio of total current asset to total

current liabilities. *t is calculated by di)iding current assets by current liabilities.

FORMULA

Current Assets

Current ratio

Current 4iabilities


52/69

St/62/*2 C-**e6t R/t5o 5enerally 2E1 is considered as ideal for the concern

CURRENT RATIO TABLE '/s. *n Crores(

Ye/*= C-**e6t A==et='R=( C-**e6t 15/3515t5e= 'R=( R/t5o

200H200


53/69

INTERPRETATION

1. The analysis sho$s that the current ratio of the com"any has been sho$ing an increasing

trend during the "eriod of the study.

2. The increase in the current ration is :.2E1 due to the increase of current assets o)er the

current liabilities.

8. The a)erage current ratio is :.2E1. 3o the com"any=s li&uidity "osition is satisfactory.

:. The current ratio re)eals that the com"any=s shortterm funds are loc%ed in current assets.


54/69

Ye/*= C-**e6t A==et= 'R=( C-**e6t 15/3515t5e= 'R=( R/t5o

200H200 1.G1 22.8< 0.8

2002007 :1. 88.G< 1.2:

20072010 101.2G 8H.G 2.G

20102011 11G. 87.G1 2.7.$> "&".%$ ).?"


55/69

INTERPRETATION

1. The analysis sho$s that the &uic% ratio $as increasing from year to year during the

"eriod of the study.

2. *n the year 20112012 the ratio $as satisfactory, because of increased &uic% assets.

8. The a)erage &uic% ratio is 2.:1E1. 3o, the li&uidity "osition of the com"any is satisfactory.

:. )er though the li&uidity "osition is good, the analysis sho$ing that there are idle funds

loc%ed in &uic% assets.


56/69

2002007 1


57/69

2. The ratio $as sho$ing an increasing trend from 20102011 to 20112012, due to

increased net sales.

8. *n the year 20072010. *t is ha)ing a less $or%ing ca"ital turno)er ratio of 1.20 times,

because of increased e"enses.

:. The a)erage $or%ing ca"ital turno)er is 1.GE1. 3o, the com"any is not efficiently

managing its $or%ing ca"ital.

ABSOLUTE LIUID RATIO

Absolute li&uid ratio is also called as cash "osition ratio. This ratio established the

relationshi" bet$een the absolute li&uid assets and current liabilities. Absolute li&uid

assets include cash in hand, cash at ban%, and mar%etable securities.

The o"timum )alue for this ratio should be one, i.e., 1E2

Fo*:-1/

A3=o1-te 15-525ty */t5o ' C/=h I6 H/62 /62 B/6 M/*et/31e Se9-*5t5e= (

C-**e6t L5/3515t5e=

ABSOLUTE LIUID RATIO TABLE '/s. *n Crores(

Ye/*= A3=o1-te 15-52

A==et='R=(

C-**e6t 15/3515t5e= 'R=( R/t5o

200H200 1.H


58/69

20112012 G.0 10.8H 0.08

A;e*/7eA3=o1-te L5-52

R/t5o

"$.? &). #.#)&

INTERPRETATION

1. By obser)ing the abo)e absolute li&uid ratio table, it is fluctuating year to during the


2. The ratio $as sho$ing an decreasing trend from 200H200 to 2002007, due to

decreased cash and ban% balances.


59/69

8. *n the year 20102011 to 20112012, the absolute li&uid ratio is in better "osition by

com"aring the other years.

:. The a)erage absolute li&uid ratio is 0.02G times. 3o, the com"any=s li&uidity "osition of

the com"any is satisfactory.

INVENTORY RATIO

*n order to ascertain that there is no o)erstoc%ing, the ratio of in)entory to $or%ing

ca"ital should be calculated. *t is $or%ed out as follo$sE

FORMULA

*n)entory

*n)entory /atio

@or%ing ca"ital

INVENTORY RATIO TABLE '/s. *n Crores(

Ye/*= I6;e6to*y 'R=( Wo*567 9/05t/1'R=( R/t5o

200H200 80.:0 0.27 0.8H

2002007 8:.


60/69

INTERPRETATION

1. The analysis sho$s that the *n)entory /atio $as decreased from year to year

during the "eriod of study.

2. *n the year 200 to 2007 the in)entory $as satisfactory, because of increased

in)entory ratio.

8. By obser)ing the abo)e *n)entory /atio table, it is fluctuating year to during the


:. 9rom the year 2002012 the ratio $as continuously decreasing.


61/69

CHAPTER ! V

CONCLUSIONS

AND

SUGGESTIONS


62/69

CONCLUSIONS

1. During the study "eriod in)entories ha)e been sho$ing an increasing trend, ece"t in the year

20112012.

2. Current assets $ere increased during the study "eriod.

8. The analysis re)eals there are more idle funds in current assets.

:. The analysis sho$s that the com"any is sho$ing more funds in &uic% assets than the re&uired


63/69

SUGGESTIONS

1. The com"any has to ta%e "ro"er measures to im"ro)e its $or%ing ca"ital "osition.

2. *t is better to offer credit facility to the same etent to its customers in order to increase

the sales.

8. The com"any has to maintain cash balances to meet daily re&uirements as "er standards.

:. The com"any has to manage current assets "ro"erly to im"ro)e li&uidity "osition.


64/69

BIBLIOGRAPHY


65/69

BIBLIOGRAPHY

TITLE OF THE BOOK AUTHOR PUBLISHERS

Management Accounting, 3hashi 5u"ta I /..3harma alyani

9inancial Management, M.6.han and P..Kain Tata Mc5ra$!ill

9inancial Management, 3.. Mahesh$ari 3ultan Chand I 3ons

WEBSITES

$$$.heterodrugs.com

$$$.moneycontrol.com
http://www.heterodrugs.com/http://www.heterodrugs.com/


66/69

APPENDI


67/69

B/1/69e =heet HETERO DRUGS Lt2.

B/1/69e Sheet !!!!!!!!!!!!!!!!!!! 56 R=. C*. !!!!!!!!!!!!!!!!!!!

M/* ") M/* "" M/* "# M/* # M/* #

12 mths 12 mths 12 mths 12 mths 12 mths

So-*9e= O8 F-62=

Total 3hare Ca"ital 2:.:< 2:.1< 12.0 .2G H.7

&uity 3hare Ca"ital 2:.:< 2:.1< 12.0 .2G H.7

3hare A""lication Money 0.00 0.00 0.00 0.00 0.08

Preference 3hare Ca"ital 0.00 0.00 0.00 0.00 0.00

/eser)es 18H. )?).)" "&.%> ).>" %."$


68/69

Contingent 4iabilities 1.0: 1.0H 0.7H 1.GH 1.27

Boo% ;alue '/s( G.G8 G.GH 12.0 G2.%."% >?.&) )).&%

PBD*T :G.10 :0.1H 8G.H1 8H.G< 2:.00

*nterest 1G.


69/69

Ta H.G :.8 7.G1 7.2 :.G

Re0o*te2 Net P*o85t ">." "$.% "&.>) ".# ">.%

Total ;alue Addition 87.:0 80.:7 2H.8< 2G.87 22.:2

Preference Di)idend 0.00 0.00 0.00 0.00 0.00

&uity Di)idend 0.00 2.:2 1.78 1.1 0.G1

Cor"orate Di)idend Ta 0.00 0.:1 0.88 0.81 0.10

Pe* =h/*e 2/t/ '/66-/15=e2(

3hares in issue 'la%hs( 2,:::.G0 2,:1

Hetero Drugs Project

Documents

Transcript of Hetero Drugs Project